Ana Paula Ribeiro Paiotti

Ana Paula Ribeiro Paiotti

Auto-generated profile, based on publicly available information

Ana Paula Ribeiro Paiotti

, Setor de Oncologia, Disciplina de Gastroenterologia, São Paulo, SP, Brasil. Universidade Federal de São Paulo Escola Paulista de Medicina Departamento de Medicina São Paulo SP Brasil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Biomédica
Verified
Journal Article
Open access
PDF file
Marcelo José Dias SilvaMarcelo José Dias Silva
Marcelo José Dias Silva
KSKarina Nascimento da Silva
Karina Nascimento da Silva
WRWillian Rodrigues Ribeiro
Willian Rodrigues Ribeiro
CFCaroline Ferreira
Caroline Ferreira
PSPatricia Sartorelli
Patricia Sartorelli
ARAna Paula Ribeiro-Paiotti
Ana Paula Ribeiro-Paiotti
Introducción. Los antiinflamatorios, inmunosupresores e inmunobiológicos se utilizan comúnmente para tratar la enfermedad intestinal inflamatoria. Sin embargo, algunos pacientes no presentan una respuesta adecuada o pierden respuesta efectiva durante el tratamiento. En un estudio reciente, se encontró un potencial efecto antiinflamatorio del extracto hidroalcohólico de Mimosa caesalpiniifolia en la colitis inducida por el ácido trinitrobenceno sulfónico utilizando ratas Wistar. Objetivo. Evaluar los efectos de la preformulación de M. caesalpiniifolia sobre la barrera intestinal durante la colitis inducida por sulfato de dextrano sódico. Materiales y métodos. Los extractos de hojas se prepararon con una solución que contenía 70 % de etanol y se secaron con un secador por aspersión Mini B19 de Buchi usando una solución con 20 % de Aerosil®. Treinta y dos ratas Wistar macho se aleatorizaron en cuatro grupos: control basal, colitis sin tratar, control con preformulación (125 mg/kg/día) y colitis tratada con preformulación (125 mg/kg/día). El índice de actividad clínica se registró diariamente y todas las ratas se sacrificaron el noveno día. Los fragmentos de colon se fijaron y se procesaron para análisis histológicos y ultraestructurales. Se recolectaron muestras de heces y se procesaron para el análisis de ácidos grasos de cadena corta. Resultados. El tratamiento con la preformulación disminuyó la actividad clínica (diarrea sanguinolenta), el infiltrado inflamatorio y las úlceras. La preformulación no reparó la barrera epitelial y no hubo diferencias significativas en el índice de células caliciformes. Se obtuvo una diferencia significativa en los niveles de butirato en las ratas tratadas con la preformulación. Conclusiones: La preformulación minimizó los síntomas clínicos de colitis e inflamación intestinal pero no minimizó el daño a la barrera intestinal.

1 January 2025 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
GSGabriel Caio DE Souza
Gabriel Caio DE Souza
HFHumberto Bezerra de Araujo Filho
Humberto Bezerra de Araujo Filho
COCleyton Zanardo DE Oliveira
Cleyton Zanardo DE Oliveira
APAna Paula Ribeiro Paiotti
Ana Paula Ribeiro Paiotti
NFNora Manoukian Forones
Nora Manoukian Forones
Background: Chemotherapy-induced diarrhea is a common and distressing side effect experienced by patients undergoing cancer treatment, particularly those with gastrointestinal cancer. It can lead to significant health complications, including dehydration, electrolyte imbalances, and treatment interruptions. Recent studies have shown that the gut microbiome plays an important role in the development and severity of chemotherapy-induced diarrhea. Modulating the gut microbiome with probiotics has emerged as a potential strategy for preventing and managing chemotherapy-induced diarrhea.

1 September 2022 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
RTRebeca De Barros Tadokoro
Rebeca De Barros Tadokoro
LCLeonardo Cardili
Leonardo Cardili
RNRicardo Artigiani Neto
Ricardo Artigiani Neto
APAna Paula Ribeiro Paiotti
Ana Paula Ribeiro Paiotti
COCelina Tizuko Fujiyama Oshima
Celina Tizuko Fujiyama Oshima
NFNora Manoukian Forones
Nora Manoukian Forones
Background: Colorectal cancer is the third cause of cancer worldwide and a quarter of them are in the rectum. DEK oncogene is involved in several nuclear processes and can accelerate tumorigenesis. Objective: This study aims to evaluate the immunoexpression of DEK and Phospho-P38 proteins before neoadjuvant therapy in patients with rectum adenocarcinoma and correlate it with a clinical response and survival. Methods: Patients with adenocarcinoma of the middle and low rectum who underwent chemotherapy and radiotherapy followed by surgical tumor resection were included. The expression and quantification were studied by immunohistochemistry in the tumor biopsy tissues using a HScore system. Score ≥4 were considered positive and those with <4 negative. Results: 22 patients were included with a mean age of 63.55 years (SD: ±13.49). The clinical-stage before treatment was T3 on 72.7%, T4 on 18.2%, 31.8% were N1, 50% N0 and all M0. After chemo and radiotherapy, 54.6% were T3; 22.7% were classified as T2; 9.1% as T1, and 13.6% were T0. Among the tumors, 22.7% were positive for DEK and 63.6% positive for Phospho-P38. There was a positive correlation between DEK protein before treatment and pTNM stage (P=0.011). Phospho-P38 protein showed no correlation with these parameters. Patients with a negative HScore had a mean survival of 141.33 months (95%CI: 112.41-170.25) and those with a positive HSscore had a mean survival of 25.10 months (95%CI: 17.36-32.84; P<0.001). Conclusion: A higher expression of DEK was observed in advanced stages. Patients who presented DEK expression <4 had a higher survival, being a factor of worst prognosis.